SCHEMBL6784688

SCHEMBL6784688

C/C(=C/C(=O)Nc1ccc(I)cc1C(=O)O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.53
PTPRC P08575 1/20 0.48
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPRA P18433 1/20 0.48
PTPRB P23467 1/20 0.48
PTPRE P23469 1/20 0.48
PTPN6 P29350 1/20 0.48
CA12 O43570 1/20 0.44
CA7 P43166 1/20 0.44
KDM4E B2RXH2 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SERPINE1 P05121 3/20 0.41
TSHR P16473 1/20 0.40
LTB4R Q15722 1/20 0.39
MEN1 O00255 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HTT P42858 3/20 0.39
KMT2A Q03164 3/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6787326 0.89 TERT (0.42) TERTKDM4ELTB4RMEN1ALDH1A1
SCHEMBL6785267 0.88 KDM4E (0.57) TERTCA12CA7KDM4EHSD17B10
SCHEMBL6783775 0.87 TERT (0.54) TERTCA12CA7KDM4EHSD17B10
SCHEMBL6785956 0.86 TERT (0.53) TERTKDM4EHSD17B10TSHRLTB4R
SCHEMBL6523512 0.84 TERT (0.72) TERTKDM4ELTB4RMEN1ALDH1A1
SCHEMBL6781172 0.84 TERT (0.51) TERTKDM4EHSD17B10SERPINE1TSHR
SCHEMBL6784687 0.83 TERT (0.77) TERTPTPRCPTPN2PTPN1PTPRA
SCHEMBL6782071 0.81 TERT (0.64) TERTPTPN1KDM4EHSD17B10TSHR
SCHEMBL6786826 0.81 TERT (0.55) TERTKDM4EHSD17B10MEN1ALDH1A1
SCHEMBL4028323 0.81 KDM4E (0.60) TERTCA12CA7KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US claimed
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885PTPRC 3408/4885PTPN2 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.